Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 8;27(6):462-468.
doi: 10.1093/oncolo/oyac061.

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma

Bassel Nazha  1   2 , Tony Z Zhuang  3 , Hiba I Dada  4 , Leylah M Drusbosky  4 , Jacqueline T Brown  1   2 , Deepak Ravindranathan  1   2 , Bradley C Carthon  1   2 , Omer Kucuk  1   2 , Jamie Goldman  1   2 , Viraj A Master  1   5 , Mehmet Asim Bilen  1   2
Affiliations

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma

Bassel Nazha et al. Oncologist. .

Abstract

Background: Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. We aimed to evaluate the feasibility of next-generation sequencing (NGS) testing of circulating cell-free tumor DNA (ctDNA) in patients with ACC, to characterize the genomic landscape of alterations, and to identify potential clinically actionable mutations.

Methods: Retrospective analysis of genomic data from 120 patients with ACC who had ctDNA testing between 12/2016 and 10/2021 using Guardant360 (Guardant Health, CA) was performed. ctDNA NGS analysis interrogated single nucleotide variants, fusions, indels, and copy number amplifications of up to 83 genes. The frequency of genomic alterations, landscape of co-occurring mutations, and pathogenic/likely pathogenic alterations with potential targeted therapies was identified. The prevalence of alterations identified in ctDNA was compared to those detected in tissue using a publicly available database (cBioPortal).

Results: The median age of this cohort was 53 years (range 21-81), and 56% of patients were female. Ninety-six patients (80%) had ≥1 somatic alteration detected. TP53 (52%), EGFR (23%), CTNNB1 (18%), MET (18%), and ATM (14%) were found to be the most frequently altered genes in ACC samples. Pathogenic and/or likely pathogenic mutations in therapeutically relevant genes were observed in 56 patients (47%) and included EGFR, BRAF, MET, CDKN2A, CDK4/6, and ATM. The most frequent co-occurring mutations were EGFR + MET (9%), MET + CDK4 (7%), EGFR + CDK4 (7%), and BRAF + MET (7%). The frequencies of mutations detected in ctDNA were similar to those detected in tissue.

Conclusions: Utilizing blood-based NGS to characterize genomic alterations in advanced ACC is feasible in over 80% of patients. Almost half of the patients had actionable mutations with approved therapies in other cancers. This approach might inform the development of personalized treatment options or identify clinical trials available for this aggressive malignancy.

Keywords: adrenal cancer; adrenocortical carcinoma; circulating tumor DNA (ctDNA); next-generation sequencing; personalized medicine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The most frequently detected genomic alterations in ACC patients, regardless of therapeutic implications. ACC, adrenocortical carcinoma.
Figure 2.
Figure 2.
Comparison of detected genomic mutations in ACC using blood-based ctDNA (Guardant database) and tissue (cBioPortal). ACC, adrenocortical carcinoma; ctDNA, circulating tumor DNA.
See this image and copyright information in PMC

References

    1. Sharma E, Dahal S, Sharma P, et al. . The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10(8):636-640. https://doi.org/10.14740/jocmr3503w - DOI - PMC - PubMed
    1. Lerario AM, Moraitis A, Hammer GD.. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2014(1-2);386:67-84. https://doi.org/10.1016/j.mce.2013.10.028 - DOI - PMC - PubMed
    1. Sturgeon C, Kebebew E.. Laparoscopic adrenalectomy for malignancy. Surg Clin North Am. 2004;84:755-774. https://doi.org/10.1016/j.suc.2004.02.003 - DOI - PubMed
    1. Fassnacht M, Dekkers OM, Else T, et al. . European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1-G46. https://doi.org/10.1530/EJE-18-0608 - DOI - PubMed
    1. Lafemina J, Brennan MF.. Adrenocortical carcinoma: past, present, and future. J Surg Oncol. 2012;106:586-594. https://doi.org/10.1002/jso.23112 - DOI - PubMed